SeltaSquare and Samsung Medical Center Launch Joint Research to Develop AI-Based Contrast Agent Adverse Reaction Prediction Model
페이지 정보
본문
— MOU Signed to Collaborate on Developing an AI-Based Contrast Agent Adverse Reaction Prediction Model
SeltaSquare (CEO: Shin Min-kyung), an AI/DX-based pharmacovigilance specialist company, and the Data Science Research Institute of Samsung Medical Center (Director: Jeong Myung-jin) announced that they signed a Memorandum of Understanding on May 23rd for the joint research and development of an AI-based prediction model for CT contrast agent adverse reactions.
The agreement is aimed at developing an AI model capable of predicting in advance the adverse reactions associated with contrast agents administered during CT imaging. The two institutions plan to collaborate on the following: investigating and analyzing the data required for model development, selecting key variables for the prediction model, and developing and validating the adverse reaction prediction model.
In particular, the partnership is expected to generate innovative synergies by combining Samsung Medical Center's extensive clinical data and medical expertise with SeltaSquare's next-generation AI/DX technology-based pharmacovigilance capabilities.
SeltaSquare is Korea's only AI/DX-based pharmacovigilance specialist company, and is developing drug safety monitoring and adverse reaction prediction solutions leveraging big data and artificial intelligence. The company has particular expertise in analyzing diverse drug adverse event patterns occurring in real-world clinical settings using AI, and in building proactive prevention systems.
Samsung Medical Center's Data Science Research Institute holds one of the largest medical big data repositories in Korea, and is equipped with strong R&D capabilities grounded in real clinical experience and data.
CEO Shin Min-kyung of SeltaSquare stated: "The integration of pharmaceutical and medical perspectives is key to accurately predicting and proactively preventing drug adverse reactions. We expect the combination of Samsung Medical Center's clinical expertise and SeltaSquare's AI/DX-based pharmacovigilance technology to extend beyond the contrast agent adverse reaction prediction model into a broad range of drug safety solutions."
Jeong Myung-jin, Director of the Data Science Research Institute at Samsung Medical Center, stated: "By combining patient data and clinical experience accumulated at the frontlines of healthcare with SeltaSquare's AI/DX-based pharmacovigilance expertise, we will develop an innovative model capable of predicting contrast agent adverse reactions in advance — contributing not only to prevention, but also to safer drug prescribing practices."
The AI-based contrast agent adverse reaction prediction model to be developed through this agreement is expected to assess individual patient risk profiles for adverse reactions prior to CT examination, supporting clinical decision-making by medical professionals and ultimately contributing to improved patient safety.
Read the Original Articles:
